ADHD Therapy for Attention Deficit Hyperactivity Disorder (ADHD)

Hassman Research Institute, Berlin, NJ
Attention Deficit Hyperactivity Disorder (ADHD)ADHD Therapy - Device
Eligibility
18 - 55
All Sexes

Study Summary

This trial tests a digital game-based therapy to treat adults with ADHD. Results will show if it's safe and effective.

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
N/A

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Study Day 0 to Study Day 63

Day 63
Adult ADHD Self-Report Scale (ASRS) Inattentive Symptoms Subscale
Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) ADHD Symptoms Total subscale
Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) Inattentive Symptoms subscale
Sheehan Disability Scale (SDS)

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

ADHD Therapy
1 of 1

Experimental Treatment

194 Total Participants · 1 Treatment Group

Primary Treatment: ADHD Therapy · No Placebo Group · N/A

ADHD Therapy
Device
Experimental Group · 1 Intervention: ADHD Therapy · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: study day 0 to study day 63

Who is running the clinical trial?

Lumos Labs, Inc.Lead Sponsor
12 Previous Clinical Trials
15,080 Total Patients Enrolled
1 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
472 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Greg Mattingly, MDPrincipal InvestigatorMidwest Research Group

Eligibility Criteria

Age 18 - 55 · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Ohio50.0%
Michigan25.0%
Kansas25.0%
What site did they apply to?
Rochester Center for Behavioral Medicine (RCBM)50.0%
Midwest Research Group50.0%
What portion of applicants met pre-screening criteria?
Met criteria66.7%
Did not meet criteria33.3%
Why did patients apply to this trial?
  • "I am 22 years old and have just recently been diagnosed with ADHD. It’s been so hard for me my whole life and I’ve never known why, until now. Anything that can possibly help and ease symptoms of ADHD are things that I would love to be apart of."
  • "I feel like I need further help managing my ADHD. I am unable to identify and address when I am being manipulated. My Family will purposely make me confused and disoriented. My Father passed away a year ago and he left money for my sister and I. It is getting taken from me by my Mother and Sister who know how to confuse me."
How many prior treatments have patients received?
033.3%
166.7%

Frequently Asked Questions

Can applicants aged younger than 55 partake in this experiment?

"In line with the criteria for inclusion, participants must be aged between 18 and 55 years old." - Anonymous Online Contributor

Unverified Answer

What are the qualifying criteria for participants of this research initiative?

"This trial has a specified criteria for eligibility: participants must have been diagnosed with attention deficit hyperactivity disorder (ADHD) and be between 18-55 years old. A total of 194 individuals are required to complete the study." - Anonymous Online Contributor

Unverified Answer

Are applications for this experiment currently being accepted?

"Affirmative. The details found on clinicaltrials.gov demonstrate that recruitment for this experiment is ongoing, with the trial first posted on March 30th 2023 and last updated on March 28th 2023. This project requires 194 individuals to be recruited from two separate healthcare facilities." - Anonymous Online Contributor

Unverified Answer

What is the scale of participants in this experiment?

"Affirmative, according to the information on clinicaltrials.gov this research effort is still accepting participants. It was originally published on March 30th 2023 and revised two days ago, with a target of 194 patients in 2 locations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.